Shengelaia Liana, Anderson Emeli J, Butsashvili Maia, Gulbiani Lasha, Kanchelashvili Giorgi, Dehovitz Jack, Djibuti Mamuka, Udo Tomoko, Kamkamidze George
Ivane Javakhishvili Tbilisi State University, Faculty of Medicine, Tbilisi, Georgia.
Health Research Union and Clinic NeoLab, Tbilisi, Georgia.
PLoS One. 2025 Sep 8;20(9):e0330764. doi: 10.1371/journal.pone.0330764. eCollection 2025.
Hepatitis C (HCV) infection is a major global health challenge, with particularly high prevalence among people who inject drugs (PWID) in the Eastern European and Central Asian region (EECA). While the country of Georgia has made major progress in reducing overall HCV prevalence, less is known about HCV reinfection rates and risk factors for reinfection among PWID. In this study, we aimed to: (1) estimate HCV reinfection rates and (2) identify risk factors associated with HCV reinfection among PWID. Data were from the 2022 Integrated Bio-Behavioral Surveillance Study (IBBS) of PWID in Georgia. For the present analysis, the sample was restricted to the 462 PWID who had previously received HCV treatment through the national elimination program. The survey included a behavioral component (face-to-face interviews using a standardized questionnaire covering injection-related risk behaviors), and a laboratory component (blood samples for HCV RNA testing). We conducted regression models based on bivariate analyses to identify risk factors associated with laboratory-confirmed HCV reinfection. Overall, the reinfection rate was 13% among PWID in our sample. We found that younger PWID had higher odds of HCV reinfection compared to older PWID. The highest reinfection rate was among participants aged 18-24, (33.3%), although this group comprised a small portion of the sample (n = 3). Those reporting public injecting, had an adjusted odds ratio AOR of 8.08 [95% CI: 2.13,30.98] of HCV reinfection. At the time of the study, continuous opioid injection every day during the last 12 months was also associated with reinfection with an AOR of 2.26 [95% CI: 1.06,5.01]. Reinfection presents a challenge to HCV elimination. We identified several key factors that may influence reinfection including age, injection environment, and duration of drug injection. These findings emphasize the necessity for an integrative approach to harm reduction that addresses both behavioral and environmental risk factors.
丙型肝炎(HCV)感染是一项重大的全球卫生挑战,在东欧和中亚地区(EECA)注射毒品者(PWID)中患病率尤其高。虽然格鲁吉亚在降低总体HCV患病率方面取得了重大进展,但关于PWID中HCV再感染率及再感染风险因素的了解较少。在本研究中,我们旨在:(1)估计HCV再感染率;(2)确定PWID中与HCV再感染相关的风险因素。数据来自2022年格鲁吉亚PWID的综合生物行为监测研究(IBBS)。对于本分析,样本仅限于462名曾通过国家消除计划接受过HCV治疗的PWID。该调查包括一个行为部分(使用涵盖注射相关风险行为的标准化问卷进行面对面访谈)和一个实验室部分(用于HCV RNA检测的血样)。我们基于双变量分析进行回归模型,以确定与实验室确诊的HCV再感染相关的风险因素。总体而言,我们样本中的PWID再感染率为13%。我们发现,与年龄较大的PWID相比,年龄较小的PWID HCV再感染几率更高。再感染率最高的是18 - 24岁的参与者(33.3%),尽管该组在样本中占比很小(n = 3)。报告在公共场所注射的人,HCV再感染的调整后优势比(AOR)为8.08 [95%置信区间:2.13, 30.98]。在研究时,过去12个月中每天持续注射阿片类药物也与再感染相关,AOR为2.26 [95%置信区间:1.06, 5.01]。再感染对消除HCV构成挑战。我们确定了几个可能影响再感染的关键因素,包括年龄、注射环境和药物注射持续时间。这些发现强调了采取综合减少伤害方法的必要性,该方法应解决行为和环境风险因素。